ClinicalTrials.gg
WithdrawnNCT07169162Updated Oct 3, 2025

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

A Phase 4 interventional study of ADZENYS XR-ODT and Placebo Oral Tablet in Attention Deficit Hyperactivity Disorder, sponsored by Aytu BioPharma, Inc.. Withdrawn at 1 site in United States. Open to participants aged 4 Years to 5 Years. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Aytu BioPharma, Inc. · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Enrollment never started

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
4 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
689th of 706
0 · median 70
Started
2019
with 31 others
Phase 4
148 of 807
18 open now
Registered
765th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 689th largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2019, is one of 148 in phase 4, and was the 765th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.

Read the detailed description

This randomized, double-blind, flexible-dose, placebo-controlled, parallel group study is designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD. Male and female children ages 4 to less than 6 years with a diagnosis of ADHD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (combined, inattentive, or hyperactive/impulsive) will be enrolled.

A Screening/Washout Period of up to 4 weeks (Days -28 to -1), which will include washout of any current ADHD medications (if applicable), will be followed by an 8-week, Randomized, Double-blind, Flexible-dose Period during which subjects will be randomly assigned to placebo or to ADZENYS XR-ODT once daily. All subjects will start on 3.1 mg of ADZENYS XR-ODT or matching placebo. The dose for each subject will be titrated in a stepwise fashion each week from Visit 3 to Visit 8 (Weeks 1 to 6) based on efficacy and tolerability to 6.3 mg; 9.4 mg; 12.5 mg; 15.7 mg; and 18.8 mg once daily, until an optimal dose or the highest dose is reached. No subject will receive a dose higher than 18.8 mg/day. Subjects must remain on a stable dose for at least 2 weeks.

An optimal dose is one that produces a reduction from Baseline of ADHD symptoms (ADHD Rating Scale IV [ADHD-RS-IV] Preschool Version) of ≥30% and a Clinical Global Impression Severity (CGI-S) score of 1 (normal), 2 (borderline ill), or 3 (mildly ill), while maintaining a tolerable adverse event (AE) profile. Once subjects reach an optimal dose of study drug, they will continue on that dose for the remainder of the study.

During titration, if a higher dose is not tolerated, the investigator may reduce the subject's dose by 1 dose level (this may not be done after Week 6 [Visit 8] of the study).

If further dose reductions are required, the subject should be discontinued from the study. Subjects who are unable to tolerate the lowest daily dose (3.1 mg) of study drug will be discontinued from the study.

Subjects who complete the 8-week Treatment Period may be eligible to enter the long-term safety and tolerability study of ADZENYS XR-ODT (NT0202.1010). For subjects to be eligible, they must complete Visit 10 without experiencing any clinically significant AEs that would preclude further exposure to ADZENYS XR-ODT. For subjects entering Study NT0202.1010, Visit 10 of this study can be Visit 1 of Study NT0202.1010, unless more than 2 weeks have elapsed since Visit 10. A safety follow-up telephone call will be made to parents/legal guardians approximately 1 week after discontinuation of study drug for subjects who do not roll over into Study NT0202.1010.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
4 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject meets criteria for ADHD, combined, hyperactive/impulsive, or inattentive presentation made during a clinical interview by an experienced clinician and confirmed with the K-SADS-PL.
  • Subject has an age- and sex-adjusted rating of ≥90th percentile Total Score on the ADHD RS-IV Preschool Version (rated over past 6 months).
  • Subject has a score of ≥4 on the CGI-S at Visit 2 (Baseline).
  • Subject has had symptoms consistent with ADHD for at least 6 months.
  • Subject has a Peabody Picture Vocabulary Test, 4th edition Standard Score of ≥70 at Visit 1 (Screening Visit).
  • Subject has undergone an adequate course of nonpharmacological treatment for ADHD based on investigator judgment or the investigator considers the subject's condition severe enough to enroll without undergoing prior nonpharmacological treatment. Subjects who have been on a previous pharmacological treatment for ADHD may be enrolled provided they meet other entrance criteria.
  • Subject has participated in structured group activity (e.g., preschool, daycare, camp) for at least 1 month that in the investigator's opinion allows assessment of symptoms and impairment in a setting outside of the home.

Exclusion criteria

Exclusion Criteria:

  • Other psychiatric diagnoses
  • Significant cognitive impairment
  • Chronic medical illnesses
  • Structural cardiac defects
  • Significant abnormal lab tests
  • Taking disallowed medications
  • Subject has history of or presence at Screening of long syndrome or QTc greater than 450 msec at Screening (using Fridericia's formula: QTcF) or any other 12-lead abnormality.
  • Subject has a history of chronic vocal or motor tics or Tourette's syndrome or a family history of Tourette's syndrome.
  • Subject has history or presence of suicidal ideation, significant self-injurious behavior, or violent behavior.
  • Subject shows evidence of current physical, sexual, or emotional abuse.
  • Subject has a height or a weight less than or equal to the 5th percentile for age and sex at the Screening Visit.
  • Subject's blood pressure measurements exceed the 95th percentile for age, sex, and height at the Screening Visits (Visit 1) and/or Baseline Visit (Visit 2) per the American Academy of Pediatrics 2017 updated guidance.
  • Subject's biological parent has a history of bipolar disorder.
  • A parent/caregiver or someone living in the subject's home has a current or recent (past 12 months) history of substance abuse.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    ADZENYS XR-ODT

    Subjects will be assigned to receive ADZENYS XR-ODT orally disintegrating tablets in a randomized manner. Subjects will receive their dose once daily in the morning. All subjects will begin taking ADZENYS XR ODT 3.1 mg per day the morning after qualifying at Visit 2. The dose for each subject will be titrated in a stepwise fashion each week through Week 6 (Visit 8) based on the investigator's judgment of subject's clinical response (i.e., efficacy and tolerability) to 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, up to 18.8 mg once daily, until an optimal dose or the highest dose is reached. No subject will receive a dose higher than 18.8 mg/day. Doses will comprise 1 or 2 tablets to achieve the (rounded) assigned dose. Once subjects reach an optimal dose of study drug, they will continue that dose for the remainder of the study.

    Drug: ADZENYS XR-ODT

  • Placebo comparator
    Placebo

    Participants in this arm will be given placebo as matching ODT once daily during the double-blind treatment period.

    Drug: Placebo Oral Tablet

Interventions

  • ADZENYS XR-ODT™ (amphetamine) is an extended-release orally disintegrating tablet approved for once-daily oral administration for the treatment of ADHD in patients 6 years and older.

  • DrugPlacebo Oral Tablet

    Participants in this arm will be given placebo as matching ODT once daily during the double-blind treatment period.

06

What researchers measure

Primary outcomes

  1. Attention-deficit/hyperactivity disorder Rating Scale-IV Preschool Version Total Score

    Attention-Deficit/Hyperactivity Disorder Rating Scale-IV: Preschool Version (ADHD-RS-IV: Preschool Version) The ADHD-RS-IV Home and School checklists consist of the nine inattention and nine hyperactive/impulsive items that comprise the ADHD symptom criteria in the DSM-IV. Each item is rated on a four-point scale (0=never or rarely to 3=very often). Scores above the 93%ile are suspicious for but not diagnostic of preschool ADHD. Boys - Parent Inattention: 14 Hyperactivity/Impulsivity: 17 Total Score: 32/Teacher Inattention: 18 Hyperactivity/Impulsivity: 22 Total Score: 38 Girls - Parent Inattention: 12 Hyperactivity/Impulsivity: 14 Total Score: 24/Teacher Inattention: 11 Hyperactivity/Impulsivity: 13 Total Score: 24

    Time frame: Visit 10/Day 56

Secondary outcomes

  1. Clinical Global Impression - Severity

    Time frame: Visit 10/Day 56

  2. Attention-deficit/hyperactivity disorder Rating Scale-IV Preschool Version Total Score

    Time frame: Visits 3-9 (Days 7, 14, 21, 28, 35, 42, 49)

  3. Clinical Global Impression - Severity

    Time frame: Visits 3-9 (Days 7, 14, 21, 28, 35, 42, 49)

Other outcomes

  1. Treatment-emergent adverse events, vital signs, clinical laboratory evaluations, and ECG results

    Occurrence of treatment-emergent adverse events; specific evaluations of vital signs (oral or tympanic temperature, sitting blood pressure (taken in triplicate and averaged), pulse, and respiratory rate); height, weight, and body mass index clinical laboratory evaluations; and 12-lead electrocardiogram results

    Time frame: Visits 3-9 (Days 7, 14, 21, 28, 35, 42, 49)

  2. Children's Sleep Habits Questionnaire (CSHQ) Subscale and Total Sleep Disturbance Scores

    The CSHQ is a psychological questionnaire designed to measure the most common sleep problems in children and adolescents 4 to 12 years of age. It contains items that relate to a number of key sleep domains that encompass the major sleep complaints in children and adolescents in this age group: bedtime behavior and sleep onset; sleep duration; anxiety around sleep; behavior occurring during sleep and night wakings; sleep-disordered breathing; parasomnias; and morning waking/daytime sleepiness. In the CSHQ, parents are asked to recall sleep behaviors that occur over a "typical" recent week. Items are rated on a 3-point scale: "usually" if the sleep behavior occurred 5 to 7 times per week; "sometimes" for 2 to 4 times per week; and "rarely" for 0 to 1 time/week. Although the entire CSHQ (Preschool and School-Aged) will be administered, the scoring will be done using the 33 Subscale items to provide Subscale and Total Sleep Disturbance scores.

    Time frame: Visits 3-9 (Days 7, 14, 21, 28, 35, 42, 49)

07

Study locations

1 site
  • Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 11, 2025
StartEst.
May 2019
Primary completionActual
Sep 5, 2025
CompletionActual
Sep 5, 2025
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07169162
Lead sponsor
Aytu BioPharma, Inc.
Collaborators
Premier Research
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
May 2019 (estimated)
Primary completion
Sep 5, 2025
Completion
Sep 5, 2025
Last update
Oct 3, 2025

Study contacts

Carolyn R Sikes, PhD
study director · Neos Therapeutics, Inc
Ann Childress, MD
principal investigator · Center for Psychiatry And Behavioral Medicine Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amphetamine

Start the discussion